Health Care Equipment and Supplies Equities Scrutiny - Abbott Laboratories, Zimmer Holdings, Varian Medical Systems, Edwards Lifesciences, and Cerus

Editor Note: For more information about this release, please scroll to bottom.

LONDON, December 11, 2014 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: Abbott Laboratories (NYSE: ABT), Zimmer Holdings Inc. (NYSE: ZMH), Varian Medical Systems Inc. (NYSE: VAR), Edwards Lifesciences Corporation (NYSE: EW), and Cerus Corporation (NASDAQ: CERS). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, December 10, 2014, ended on a negative note as the Dow Jones Industrial Average finished at 17,533.15, down 1.51% and the NASDAQ Composite closed at 4,684.03, down 1.73%. The S&P 500 finished the session 1.64% lower at 2,026.14. During the trading session, all the ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 803.98, down 1.59%, whereas the index has advanced 8.03% in the previous three months. Register for your complimentary reports on these five stocks at:  

http://investor-edge.com/register

Abbott Laboratories' stock lost 2.35%, to close the day at $44.37. The stock recorded a trading volume of 5.48 million shares, above its three months average volume of 5.03 million shares. The company's shares oscillated between $44.33 and $45.46 during the session. Over the last one month and over the past three months, Abbott Laboratories' shares have advanced 0.64% and 3.43%, respectively. Further, the stock has gained 15.76% since the start of this year. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $43.08 is above its 200-day moving average of $41.18. Additionally, the stock traded at a PE ratio of 29.28 and has a Relative Strength Index (RSI) of 64.06. Sign up and read the free notes on ABT at:

http://get.Investor-Edge.com/pdf/?c=Abbott%20Laboratories&d=11-Dec-2014&s=ABT

On Wednesday, shares in Zimmer Holdings Inc. recorded a trading volume of 0.92 million shares, lower than its three months average volume of 1.10 million shares. The stock ended the day at $111.51, which was 1.95% below its previous day's closing of $113.73, and registered an intraday range of $111.26 and $113.83. Shares of the company traded at a PE ratio of 19.22. Zimmer Holdings Inc.'s shares have gained 0.99% in the last one month, 6.45% in the previous three months, and 19.66% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $107.08 and $101.75, respectively. Furthermore, shares of Zimmer Holdings Inc. have an RSI of 61.41. The complimentary notes on ZMH can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Zimmer%20Holdings&d=11-Dec-2014&s=ZMH

Shares in Varian Medical Systems Inc. fell 2.53% to end Wednesday's session at $86.60. The stock recorded a trading volume of 0.68 million shares, below its three months average volume of 0.79 million shares. The company's shares fluctuated between $86.58 and $89.00 during the session. Shares of the company traded at a PE ratio of 21.91. Varian Medical Systems Inc.'s shares have gained 11.47% since the beginning of 2014. Further, the stock has advanced 1.50% over the last one month and 0.79% in the previous three months. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $84.12 is above its 200-day moving average of $83.39. Additionally, the stock has an RSI of 64.25. Register for free on Investor-Edge and access the latest research on VAR at:

http://get.Investor-Edge.com/pdf/?c=Varian%20Medical%20Systems&d=11-Dec-2014&s=VAR

On Wednesday, shares in Edwards Lifesciences Corp. fluctuated between $130.11 and $133.95 before ending the session 2.33% lower at $130.37. The stock reported a trading volume of 0.92 million shares, close to its three months average volume of 0.90 million shares. Shares of the company traded at a PE ratio of 44.97. Edwards Lifesciences Corp.'s stock has gained 4.63% in the last one month, 29.71% in the previous three months, and 98.25% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $117.39 and $93.38, respectively. Moreover, shares of Edwards Lifesciences Corp. have an RSI of 71.63. The complete research on EW is available for free at:

http://get.Investor-Edge.com/pdf/?c=Edwards%20Lifesciences&d=11-Dec-2014&s=EW

Cerus Corp.'s stock finished Wednesday's session 1.76% higher at $4.62. A total of 2.18 million shares were traded, which was above its three months average volume of 1.07 million shares. The stock vacillated between $4.47 and $4.77 during the session. Over the last one month and over the past three months, Cerus Corp.'s shares have gained 14.64% and 12.41%, respectively. However, from the beginning of 2014, the stock has declined 28.37%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $4.30 is greater than its 50-day moving average of $4.15. Cerus Corp.'s stock has an RSI of 63.57. Free in depth research on CERS is available at:

http://get.Investor-Edge.com/pdf/?c=Cerus&d=11-Dec-2014&s=CERS

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Investor-Edge

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.